KRAS-variant

Pills in a bottle to represent medication

Clinical Trial for Patients with the KRAS-variant and HNSCC

Here on MiraKind.org, we’ve already discussed how the KRAS-variant plays a role in breast cancer risk, ovarian cancer risk, effects of HRT in the KRAS-variant patients, and even autoimmunity! Now, we want…

Read More ➝
doctor with tablet pc computer at office

New Partnership Alert: MiraKind & gennev

MiraKind is committed to providing our community with the best tools possible to tackle challenges in the arena of women’s health. This is why MiraKind is partnering with gennev, a first-of-its-kind telehealth…

Read More ➝
White blood cells of a human, photomicrograph panorama as seen under the microscope, 1000x zoom.

Important Findings From Our Recently Published KRAS-Variant Study

A new study by MiraKind’s Founder, Dr. Joanne Weidhaas, in collaboration with her team at the University of California, Los Angeles and City of Hope, has been published in the scientific journal…

Read More ➝
MiraKind Ask me Anything

How Do I Get My DNA Test (KRAS-variant) Results?

Video 3 in our Ask Me Anything Series: Dr. Joanne Weidhaas answers your questions in our Ask Me Anything video series. Have a Question for Dr. Joanne? Submit your Q here

Read More ➝
MiraKind Ask me Anything

Do I need to get tested for KRAS-variant if I’m BRCA positive?

  Video 2 in our Ask Me Anything Series: Dr. Joanne Weidhaas answers your questions in our Ask Me Anything video series. Have a Question for Dr. Joanne? Submit your Q here

Read More ➝
MiraKind Ask me Anything

KRAS-Variant and Breast Cancer

Webinar – KRAS-Variant and Breast Cancer Did you miss our live webinar on the KRAS-Variant with Dr. Joanne Weidhaas? Watch the replay and learn about how this genetic mutation can impact your…

Read More ➝
Scientist using multi-channel pipette for pipetting a 96 well plate with red solution on blue.

New Research: How Inherited DNA -Based Mutations Impact Immunotherapy

The partners on the UCLA research team have made new discoveries about how genetic mutations can help doctors predict patient responses to cancer-fighting immunotherapy drugs. In the past, we have spoken a…

Read More ➝
MiraKind Ask me Anything

HRT and The KRAS-Variant

While there are many factors to consider before taking hormone replacement therapy (HRT), understanding your genetic profile can prove invaluable in your decision-making process. Joanne Weidhaas, MD, PhD, and her colleagues published…

Read More ➝
Test tubes

What You Need to Know About Estrogen and the KRAS-variant

Joanne Weidhaas is MiraKind’s founder and one of the scientists responsible for discovering the KRAS-variant, an inherited genetic mutation which predicts an increased risk of cancer. Following this breakthrough, Weidhaas and her…

Read More ➝
MiraKind Ask me Anything

Why you should get your KRAS-variant results

Dear study participants, I wanted to share an experience that I had today. I had a wonderful conversation with a woman who participated in the first MiraKind study.  While I always enjoy…

Read More ➝
Samples in a lab

The truth about GWAS and the KRAS-variant

Although much of the world has accepted that GWAS studies, which use an outdated technology looking at large amounts of data, have failed to find any functional mutations, this approach has twice…

Read More ➝
Dr. Joanne Weidhass, Discover Magazine

How does breast cancer treatment impact second breast cancer risk?

We are embarking on a study to explore how breast cancer management strategies (e.g., chemotherapy, surgery, hormones) that are used to treat breast cancer, impact breast cancer risk for women with the KRAS-variant.

Read More ➝
curve-up2
arrow up to top